lifestyle.celebhomes.net
Home
Sample Page
Author:
Revolution Medicines, Inc.
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
April 13, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
April 2, 2026
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 4, 2026
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 29, 2026
←
Previous Page
1
2